When should a child start myopia treatment?

The IMI 2025 consensus recommends initiating myopia management at the time of diagnosis, not waiting for progression to become 'fast enough.' Early onset (before age 10), presence of both myopic parents, and axial length at or above the 75th percentile for age are all indications to start treatment promptly.

Is it too late to start myopia treatment at age 14?

No — treatment at any age during active growth phases produces measurable benefit. However, the benefit is lower because older children have less remaining growth. A child starting treatment at 14 will gain 3–5 fewer years of slowed progression compared to one who starts at 8.

What triggers the decision to start myopia treatment?

Clinical triggers include: prescription change of more than −0.50D per year, axial length growth above 0.20mm per year, axial length above the 75th percentile for age and ethnicity, age of onset before 10, and presence of both myopic parents. Any one of these is considered sufficient grounds to begin management.

Home › Resources › When to start myopia treatment

MyopiaTracker Clinical Team

Reviewed by B. Vasudevan, BSOptom, PhD, MBA · Last updated: April 2026

When Should My Child Start Myopia Treatment?

Short answer: Earlier is better — especially under age 10. The IMI 2025 global consensus has shifted away from "watchful waiting." If your child has any risk factor for rapid progression, the current evidence supports starting treatment at the time of diagnosis, not after the situation worsens.

For clinicians: Looking for the IMI 2025 clinical update and what changed in the guidelines? Read the IMI 2025 clinical summary →

The clinical triggers for starting treatment

Clinicians typically consider myopia management when one or more of the following are present. Any single trigger is considered sufficient — you do not need all of them.

⚡
Fast progression — prescription change >−0.50D/year A full half-diopter change in a single year is above the threshold most guidelines consider "active." In terms of axial length, this corresponds to roughly 0.20–0.25mm/year of eye growth.
👶
Young age of onset — myopia diagnosed before age 10 A child who becomes myopic at age 7 has 10+ years of active eye growth ahead. Even at moderate progression rates, this compounds to very high myopia by adulthood. Earlier onset = more urgent management.
📏
Elevated axial length — at or above 75th percentile for age/ethnicity Axial length above average signals structural risk independently of prescription speed. An eye already in the upper quartile for its age is further from the structural safe zone.
👨‍👩‍👧
Both parents myopic The risk of reaching high myopia (above −6D) is substantially higher when both parents are myopic. This genetic load justifies earlier intervention even when current progression appears mild.
📱
High near-work load + low outdoor time More than 3 hours/day of near work combined with less than 90 minutes of outdoor time is an environmental risk profile that augments all other risk factors.

The IMI 2025 position: "Myopia management is no longer optional for children with active progression. The question is not whether to treat, but which treatment fits this patient's risk profile and lifestyle." — Editorial summary of IMI 2025 Digest consensus.

Why age matters so much

The eye grows fastest between ages 7 and 12. This is the window where treatment delivers the most cumulative benefit — because slowing growth during the fastest phase prevents the most permanent elongation.

Age 6–8

Highest treatment urgencyRapid growth phase beginning. Any fast progression here compounds dramatically. Starting now provides 10+ years of benefit.

Age 9–12

Peak treatment benefit windowStill in the fast growth phase. Starting during this window typically prevents 0.5–1.5mm of unnecessary axial elongation over the remaining childhood years.

Age 13–16

Still worthwhileGrowth slows but doesn't stop. Treatment still reduces progression and final adult refraction. Less total benefit than starting earlier, but not negligible.

Age 17+

Declining returnsEye growth typically decelerates in late teens. Treatment benefit diminishes. Most clinicians reassess necessity, though some patients continue until 21.

What "wait and see" actually costs

One year of untreated fast progression at +0.30mm/year adds permanently to lifetime axial length. Over 3 years of delay in a fast-progressing 8-year-old, that's approximately 0.9mm of avoidable eye elongation — which could mean the difference between −5.00D and −7.00D at adulthood, and between moderate and high structural risk.

Risk stratification at a glance

🔴 High urgency — treat now

Under age 10 with any active progression
Growth >0.30mm/year axial length
AL already above 25mm in a child
Both parents myopic + fast progressor

🟡 Moderate urgency — treat proactively

Ages 10–13 with measurable progression
Growth 0.15–0.30mm/year
AL between 50th and 75th percentile
One myopic parent + near-work heavy lifestyle

🟢 Lower urgency — monitor closely

Age 14+ with slow progression
Growth <0.10mm/year
AL below 50th percentile for age
No significant risk factors

Not sure which category your child falls into?

Enter their age, current axial length, and prior measurement. MyopiaTracker calculates growth rate, percentile, and risk classification — and shows projected outcomes with and without treatment.

Check your child's risk level now →

Questions to ask your optometrist

What is my child's axial length, and is it above average for their age?
How fast has the axial length grown since the last visit?
Based on this rate, what prescription do you project by age 18?
Which myopia management options do you offer?
If we start treatment now vs. waiting 6 months, what difference does that make?

Check if your child needs treatment now

Enter axial length measurements from any two visits. Get a growth rate, percentile ranking, and projected adult prescription — with and without treatment. Free, no login required.

Check risk now → Compare treatments →

This page is for educational purposes only. MyopiaTracker is a decision-support tool — not a diagnostic device or substitute for professional clinical assessment. The IMI 2025 paraphrase reflects the editorial interpretation of publicly available consensus documents; refer to original IMI publications for clinical decisions. Consult a qualified optometrist or ophthalmologist for personalised advice.